David Strayer

David R. Strayer, M.D. is the Chief Scientific & Medical Officer of Hemispherx Biopharma, the makers of Ampligen. Formerly a Professor of Medicine at the Medical College of Pennsylvania and Hahnemann University from 1987 to 1998. Board Certified in Medical Oncology and Internal Medicine with research interests in the fields of cancer and immune system disorders. Principal investigator in studies funded by the Leukemia Society of America, the American Cancer Society, and the National Institutes of Health.

Notable studies

 * 1994, Ampligen inhibits human herpesvirus-6 in vitro (Abstract)
 * 1994, A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome (Abstract)
 * 1995, Long Term Improvements in Patients with Chronic Fatigue Syndrome Treated with Ampligen (Abstract)
 * 2001, Assessment of Functional Impairment by Cardiopulmonary Exercise Testing in Patients with Chronic Fatigue Syndrome (Abstract)
 * 2005, Exercise capacity and immune function in male and female patients with Chronic Fatigue Syndrome [(Full Text)
 * 2007, Cross-Protection against H5N1 Influenza Virus Infection Is Afforded by Intranasal Inoculation with Seasonal Trivalent Inactivated Influenza Vaccine (Abstract)
 * 2012, A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome (Full Text)
 * 2015, Low NK Cell Activity in Chronic Fatigue Syndrome (CFS) and Relationship to Symptom Severity (Full Text)
 * 2015, Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME): Characteristics of Responders to Rintatolimod (Full Text)